Protagonist Therapeutics PTGX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's investing cash flow?
- Protagonist Therapeutics (PTGX) reported investing cash flow of $90.89M in Q1 2026.
- How has Protagonist Therapeutics's investing cash flow changed year-over-year?
- Protagonist Therapeutics's investing cash flow increased by 196.3% year-over-year, from -$94.4M to $90.89M.
- What is the long-term trend for Protagonist Therapeutics's investing cash flow?
- Over 2 years (2022 to 2024), Protagonist Therapeutics's investing cash flow has grown at a 80.9% compound annual growth rate (CAGR), from $91.47M to -$299.48M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.